ARTICLE | Clinical News
Guadecitabine: Phase I/II started
August 22, 2016 7:00 AM UTC
Cancer Research UK began the double-blind, placebo-controlled, U.K. Phase I/II SPIRE trial to evaluate subcutaneous guadecitabine from Otsuka’s Astex Pharmaceuticals Inc. subsidiary plus cisplatin a...